Clinical Trial Update: Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH) [Phase 2]

View source ↗

Summary

Phase 2 interventional study evaluating infigratinib for achondroplasia in children under 3 years old; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Achondroplasia

Drugs mentioned

• Infigratinib (infigratinib)

Snippet

Sponsor: QED Therapeutics, a BridgeBio company | Conditions: Achondroplasia | Phase 2 | Status: RECRUITING